Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension
D5982C00008
Phase 3 small_molecule active
Quick answer
Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension for Severe and inadequately controlled asthma is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Severe and inadequately controlled asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active